Lexicon Pharma reports that the pivotal inTandem1 Phase 3 clinical trial of sotagliflozin met its primary endpoint :
Top-line results from the Phase 3 study showed that patients treated with sotagliflozin had a mean A1C reduction from baseline of 0.43% on 200mg once daily sotagliflozin dose (p
- Sanofi (SNY) stated, "These top-line results highlight potential benefits of sotagliflozin when treating adults with type 1 diabetes. We congratulate our partners on this positive outcome and look forward to further exploring this compound for the treatment of adults with type 2 diabetes when Sanofi begins the Phase 3 program later this year."
No comments:
Post a Comment